Trials / Terminated
TerminatedNCT05348681
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Aristea Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RIST4721 | RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2022-07-18
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2022-04-27
- Last updated
- 2023-06-13
- Results posted
- 2023-06-13
Locations
12 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05348681. Inclusion in this directory is not an endorsement.